vidarabine has been researched along with Cytokine Release Syndrome in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atanackovic, D; Bukhari, A; Dahiya, S; Gahres, N; Gottlieb, D; Hardy, NM; Holtzman, NG; Kansagra, AJ; Kim, DW; Kocoglu, MH; Law, JY; Lee, ST; Lutfi, F; Matsumoto, LR; Mohindra, P; Molitoris, J; Mustafa Ali, M; Rapoport, AP; Ruehle, K; Samanta, S; Yan, J; Yared, JA | 1 |
| Avivi, I; Bot, A; Bouabdallah, K; Dong, J; Dührsen, U; Houot, R; Kerber, A; Kersten, MJ; Kim, JJ; Kuruvilla, J; Lugtenburg, PJ; Minnema, MC; Plaks, V; Rossi, JM; Sherman, M; Song, KW; Thieblemont, C; Topp, MS; van Meerten, T; Vardhanabhuti, S; Wermke, M; Zheng, Y | 1 |
| Cao, J; Cheng, H; Gao, X; Jiao, J; Li, D; Li, W; Li, Z; Liu, H; Ma, Y; Qin, Y; Sang, T; Sang, W; Shi, M; Song, X; Sun, C; Sun, H; Sun, K; Wang, Y; Wu, M; Xu, K; Xu, L; Yan, D; Yan, Z; Yang, J; Yao, M; Zeng, L; Zhang, B; Zheng, J; Zhu, F | 1 |
| Bar, M; Bezerra, ED; Cassaday, RD; Chapuis, AG; Chou, CK; Cowan, AJ; Fiorenza, S; Gauthier, J; Green, DJ; Hawkins, RM; Hirayama, AV; Jamieson, AW; Kiem, HP; Kimble, EL; Maloney, DG; Milano, F; Pender, BS; Phi, TD; Riddell, SR; Shadman, M; Sheih, A; Steinmetz, RN; Till, BG; Turtle, CJ; Vakil, A | 1 |
| Cui, Q; Hu, Y; Huang, H; Liang, Z; Shao, M; Wu, Z; Xiao, L; Zhang, H | 1 |
3 trial(s) available for vidarabine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Biological Products; Biomarkers; Cyclophosphamide; Cytokine Release Syndrome; Drug Therapy, Combination; Female; Humans; Immunotherapy, Adoptive; Leukapheresis; Levetiracetam; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nervous System Diseases; Neutropenia; Propensity Score; Vidarabine; Young Adult | 2021 |
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 Ratio; Confidence Intervals; Cyclophosphamide; Cytokine Release Syndrome; Female; Glycolysis; Humans; Ifosfamide; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Progression-Free Survival; Receptors, Chimeric Antigen; Recurrence; T-Lymphocytes; Thrombocytopenia; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Topics: Adult; Aged; Antigens, CD19; Cell Proliferation; Cyclophosphamide; Cytokine Release Syndrome; Female; Humans; Immunotherapy, Adoptive; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Progression-Free Survival; T-Lymphocytes; Treatment Outcome; Vidarabine | 2021 |
2 other study(ies) available for vidarabine and Cytokine Release Syndrome
| Article | Year |
|---|---|
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modality Therapy; Cyclophosphamide; Cytokine Release Syndrome; Female; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Leukapheresis; Lymphocyte Depletion; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Pancytopenia; Progression-Free Survival; Receptors, Antigen, T-Cell; Retrospective Studies; Salvage Therapy; Vidarabine | 2021 |
Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.
Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytokine Release Syndrome; Humans; Lymphocyte Depletion; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Remission Induction; T-Lymphocytes; Vidarabine | 2020 |